Skip to main content
BioCentury on BioBusiness
Feature Story

Ironwood's local notion

How tissue-targeting may add new indications for Ironwood compounds

By Emily Cukier-Meisner, Senior Writer

Ironwood Pharmaceuticals Inc. is exploring how tissue-specific distribution can give its products additional activity or different clinical profiles suitable for new indications. The company reported Phase I data last week for IW-1973, a stimulator of soluble guanylate cyclase that was designed to leave the vasculature and enter tissues to treat cardiovascular diseases.

Ironwood also is altering biodistribution to make next-generation versions of constipation drug Linzess linaclotide that will have different clinical profiles depending on where they act within the GI tract.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.